ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Prognostic model construction and drug prediction in colorectal cancer using mitochondrial programmed cell death-related genes.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is a highly aggressive and heterogeneous malignancy with a poor prognosis. Mitochondria and programmed cell death (PCD) play crucial roles in CRC tumorigenesis and cancer progression. However, the prognostic significance of mitochondrial programmed cell death (MPCD) remains unclear. This study aims to investigate prognostic value of MPCD-related genes.
methodsCRC patient data from The Cancer Genome Atlas (TCGA) and MPCD gene sets from previous studies were collected. A prognostic model based on MPCD-related genes was developed using regression analysis and validated using an external CRC cohort from Gene Expression Omnibus (GEO). Immune microenvironment of the two risk cohorts was evaluated using ssGSEA and CIBERSORT algorithms. Potential anti-tumor drugs targeting model genes were predicted using pRRophetic R package. In addition, CRC-related cell lines were collected, and functional tests were conducted on the key risk gene SRPX.
resultsA prognostic model comprising 13 MPCD genes (ACSL6, ELANE, G6PC2, ITGB3, MTM1, NAT1, PLAU, SCG2, SLC7A11, SMPD1, SRPX, TPM1, TRAP1) was successfully constructed, which demonstrated stable prognostic performance across different CRC cohorts. Immune infiltration analysis revealed significant enrichment of Tregs and Tfh cells in the high-MPCD cohort, suggesting that immune tolerance may contribute to the poor prognosis in this group. Three candidate drugs-CGP-60474, WH-4-023, and Trametinib-were identified as having significant negative correlations with model genes SRPX, SCG2, and SMPD1. Cell experiments demonstrated that overexpression of SRPX significantly inhibited the migration and invasion abilities of HCT116 cells.
conclusionThis study developed an independent and reliable MPCD-related prognostic model. The model provides new targets for personalized risk assessment and immunotherapeutic interventions in CRC.
Indexed as
Identifiers
42184077What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.